Chakravartty, Arunava
24Novartis Pharmaceuticals Corporation, East Hanover, NJ;
3 papers on CoChat
Most cited papers
- Verified
Overall survival with ribociclib plus endocrine therapy in breast cancer
Im, S.-A., Lu, Y.-S., Bardia, A., Harbeck, N., Colleoni, M., Franke, F., Chow, L., Sohn, J., Lee, K.-S., Campos-Gomez, S., et al. (2019) · New England Journal of Medicine
Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies
Cited by 1,001
- Verified
Overall survival with ribociclib plus fulvestrant in advanced breast cancer
Slamon, D. J., Neven, P., Chia, S., Fasching, P. A., De Laurentiis, M., Im, S.-A., Petrakova, K., Bianchi, G. V., Esteva, F. J., Martín, M., et al. (2020) · New England Journal of Medicine
Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies
Cited by 865
- Verified
Abstract PD2-04: Updated overall survival (OS) results from the phase III MONALEESA-7 trial of pre- or perimenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib
Tripathy, D., Im, S.-A., Colleoni, M., Franke, F., Bardia, A., Harbeck, N., Hurvitz, S., Chow, L., Sohn, J., Lee, K. S., et al. (2021) · Cancer Research
Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies
Cited by 30
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free